| pubmed-article:14964 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C0220806 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C0206325 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C0019602 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C0031667 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C1709915 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C1533148 | lld:lifeskim |
| pubmed-article:14964 | lifeskim:mentions | umls-concept:C1554963 | lld:lifeskim |
| pubmed-article:14964 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:14964 | pubmed:dateCreated | 1977-5-27 | lld:pubmed |
| pubmed-article:14964 | pubmed:abstractText | Reaction of phospholipase A2 (Naja naja naja) with p-bromophenacyl bromidine leads to almost complete loss of enzymatic activity. The rate of inactivation is pH-dependent with pKa equals 6.9 for the ionizing residue. p-Bromophenacyl bromide modifies 0.5 mol of histidine/mol of enzyme as judged by amino acid analysis and incorporation studies with 14C-labeled reagent. The rate of inactivation is affected by various cations; a saturating concentration of Ca2+ decreases the rate 5-fold, while Mn2+ increases the rate by a factor of 2. Triton X-100, which by itself has little affinity for the enzyme, protects against inactivation, presumably by sequestering p-bromophenacyl bromide into the apolar micellar core. The mixed micelle system of Triton X-100, dipalmitoyl phosphatidylcholine, and Ba2+ offers the best protection, lowering the inactivation rate by at least 50-fold. This suggests an active site role for the histidine residue. Ethoxyformic anhydride also modifies phospholipase A2, by acylation of the two amino groups, a tyrosine, and 0.5 mol of histidine/mol of enzyme without totally inactivating the enzyme. Removal of the ethoxyformyl group from the histidine does not reactivate the enzyme. Thus, modification of 0.5 mol of histidine with this reagent is not responsible for the 85% loss of activity seen. Ethoxyformylated enzyme, with 0.5 mol of acylated histidine/mol of enzyme, can be further inactivated by treatment with p-bromophenacyl bromide. The resulting derivative contains 0.4 mol of the 14C-labeled p-bromophenacyl group. Other modifiable groups do not show this half-residue reactivity. For example, oxidation of phospholipase A2 with N-bromosuccinimide leads to rapid destruction of 1.0 tryptophan residue and 5% residual activity. The results of these chemical modification experiments can be interpreted in terms of a model in which the active species of enzyme interacting with mixed micelles is a dimer (or possibly higher order aggregate). The dimer, though composed of identical subunits, is asymmetric; the histidine of one subunit is accessible to ethoxyformic anhydride, while the other histidine is near a hydrophobic region of the enzyme and is chemically reactive toward p-bromophenacyl bromide. | lld:pubmed |
| pubmed-article:14964 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14964 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14964 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14964 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:14964 | pubmed:issn | 0021-9258 | lld:pubmed |
| pubmed-article:14964 | pubmed:author | pubmed-author:RobertsM FMF | lld:pubmed |
| pubmed-article:14964 | pubmed:author | pubmed-author:DennisE AEA | lld:pubmed |
| pubmed-article:14964 | pubmed:author | pubmed-author:DeemsR ARA | lld:pubmed |
| pubmed-article:14964 | pubmed:author | pubmed-author:MinceyT CTC | lld:pubmed |
| pubmed-article:14964 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14964 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:14964 | pubmed:volume | 252 | lld:pubmed |
| pubmed-article:14964 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14964 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14964 | pubmed:pagination | 2405-11 | lld:pubmed |
| pubmed-article:14964 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-An... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Hy... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Ca... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Hi... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Ph... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Ph... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Ki... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Sn... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Po... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Pr... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Bi... | lld:pubmed |
| pubmed-article:14964 | pubmed:meshHeading | pubmed-meshheading:14964-Ca... | lld:pubmed |
| pubmed-article:14964 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:14964 | pubmed:articleTitle | Chemical modification of the histidine residue in phospholipase A2 (Naja naja naja). A case of half-site reactivity. | lld:pubmed |
| pubmed-article:14964 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14964 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:14964 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14964 | lld:pubmed |
